Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Pathology · Hypocomplementemic Urticarial Vasculitis Syndrome

Diagnosis and Pathology: Solving the HUVS Puzzle

At a Glance

HUVS is diagnosed by combining recurring hives, persistently low complement levels, symptoms or organ findings, and supportive skin-biopsy results. Anti-C1q antibodies can help, but a negative test does not rule out HUVS.

Confirming a diagnosis of Hypocomplementemic Urticarial Vasculitis Syndrome (HUVS) requires a careful, comprehensive evaluation. Because no single blood test can definitively prove you have HUVS, doctors synthesize your clinical history, physical examination, blood work, and microscopic tissue analysis [1][2].

The Diagnostic Framework (Schwartz Criteria)

Historically, many specialists reference the Schwartz criteria to classify HUVS. These are clinical references, not a universally adopted, definitive diagnostic test. In this framework, a diagnosis typically requires both major criteria and at least two minor criteria [2]:

  • Major Criteria:
    1. Chronic Urticaria: Hives or hive-like lesions that have been recurring for at least 6 months [2].
    2. Hypocomplementemia: Persistently low levels of complement proteins in the blood [2].
  • Minor Criteria:
    • Venulitis: Evidence of blood vessel inflammation on a skin biopsy [2].
    • Arthralgia or Arthritis: Joint pain or swelling [2].
    • Ocular Inflammation: Redness or pain in the eyes (uveitis or episcleritis) [2].
    • Abdominal Pain: Recurring stomach pain [2].
    • Glomerulonephritis: Evidence of kidney inflammation [2].
    • Anti-C1q Antibodies: The presence of specific antibodies that target the C1q protein [2].

Auditing Your Blood Work

When reviewing your lab results, pay close attention to the complement system markers. In HUVS, your immune system consumes these proteins [3].

  • Complement C3 and C4: These are general complement tests. Low levels suggest the immune system is active [1].
  • C1q Level: A low C1q level may support the diagnosis and is considered by some to be a sensitive marker [1].
  • Anti-C1q Antibody: This test looks for a specific autoantibody. While it is a hallmark of the disease, it is only positive in some patients with HUVS [1][4]. A negative result does NOT rule out HUVS [1].
  • Differentiating from Lupus (SLE): HUVS can overlap with Systemic Lupus Erythematosus (SLE). Doctors will often run tests for ANA (Antinuclear Antibody) and anti-dsDNA. While ANA is common in many conditions, SLE is diagnosed using the entire clinical picture—including symptoms, organ involvement, and specific antibody profiles—not just a single laboratory cutoff [5][2].

The Skin Biopsy: What the Pathologist Sees

A skin biopsy is a supportive test to confirm vasculitis. Decisions about when to biopsy belong to the treating clinician. For the best chance of an accurate result, the biopsy is usually taken from a fresh lesion (less than 24 to 48 hours old) [6]. A negative or poorly timed biopsy does not completely rule out the disease.

When you read your pathology report (H&E stain), look for these key technical terms describing Leukocytoclastic Vasculitis (LCV):

  • Neutrophil-rich infiltrate: An abundance of white blood cells (neutrophils) surrounding the blood vessels [7].
  • Leukocytoclasia: Also called “nuclear dust,” referring to the fragmented remains of white blood cells [7][8].
  • Fibrinoid Necrosis: Damage to the blood vessel wall where it starts to break down and is replaced by fibrin [7][8].
  • Erythrocyte Extravasation: Red blood cells that have leaked out of the damaged vessels, causing the bruising look [9].

Diagnostic Completeness Checklist

Your care team will likely run a variety of tests. Here is a guide to what they evaluate:

Test Category Specific Test Why It Matters
Tissue Skin Biopsy (H&E stain) A supportive test for blood vessel inflammation (vasculitis) [7].
Tissue Direct Immunofluorescence (DIF) Looks for immune deposits (like C4d or immunoglobulins) in the skin [10].
Complement C3 and C4 Levels Measures general immune complement status [1].
Complement C1q Quantitative Level Evaluates specific complement reduction [1].
Antibodies Anti-C1q Antibody Supportive if positive, but not required for diagnosis [1].
Autoimmune ANA, anti-dsDNA, anti-Sm Part of the broader clinical evaluation to distinguish from or identify overlapping Lupus (SLE) [2].
Organ Screen Urinalysis (UA) Checks for blood or protein that could indicate kidney involvement [11].
Organ Screen CBC and Metabolic Panel Monitors overall health, cell counts, and kidney function (Creatinine) [12].

Common questions in this guide

How is HUVS diagnosed?
Doctors combine your symptoms, physical examination, blood tests, and sometimes a skin biopsy because no single test proves HUVS. Historically, the Schwartz framework uses chronic hives and persistently low complement as major criteria, plus at least two additional findings such as vessel inflammation, joint symptoms, eye inflammation, abdominal pain, kidney inflammation, or anti-C1q antibodies.
What do complement and anti-C1q tests show in HUVS?
C3 and C4 measure general complement levels, while a C1q level evaluates a specific complement protein. The anti-C1q test looks for an antibody directed at C1q; a positive result can support HUVS, but a negative result does not rule it out.
What can a skin biopsy show in HUVS?
A biopsy may show leukocytoclastic vasculitis, meaning inflammation and damage in small blood vessels. The report may mention neutrophils, nuclear dust from broken-down white blood cells, fibrinoid necrosis, or red blood cells leaking from vessels. A sample from a fresh lesion, usually less than 24 to 48 hours old, gives the best chance of finding these changes.
Why does the timing of a HUVS skin biopsy matter?
The skin changes of vasculitis can become less visible as a lesion ages, so clinicians often select a lesion that is less than 24 to 48 hours old. A negative result or a biopsy taken from an older lesion does not completely exclude HUVS.
How do doctors check for lupus overlap with HUVS?
Doctors may order ANA, anti-dsDNA, and anti-Sm tests and assess symptoms, organ involvement, urine findings, and other clinical information. Systemic lupus erythematosus is not diagnosed from one antibody result or a single laboratory cutoff.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my skin biopsy specifically show evidence of 'leukocytoclasis' or 'fibrinoid necrosis' in the small blood vessels?
  2. 2.Was the C1q level itself measured, or just the anti-C1q antibody? How do these results compare to my C3 and C4 levels?
  3. 3.Given my lab results, do I meet the criteria for a formal diagnosis of HUVS based on historical clinical frameworks?
  4. 4.Do my ANA and anti-dsDNA results suggest an overlap with systemic lupus erythematosus (SLE), and how does that change my monitoring plan?
  5. 5.Was direct immunofluorescence (DIF) performed on my biopsy, and did it show C4d or other immune deposits?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    [Hypocomplementemic urticarial vasculitis].

    Jachiet M, Flageul B, Bouaziz JD, et al.

    La Revue de medecine interne 2018; (39(2)):90-98 doi:10.1016/j.revmed.2017.03.005.

    PMID: 28457680
  2. 2

    Urticarial hypocomplementemic vasculitis syndrome and systemic lupus erythematosus: a case report and review of the literature.

    Ouerdani Y, Ben Achour T, Ben Hmid A, et al.

    Frontiers in immunology 2025; (16()):1649699 doi:10.3389/fimmu.2025.1649699.

    PMID: 40852710
  3. 3

    Correct approach in urticarial vasculitis made early diagnosis of lupus nephritis possible: a case report.

    Smets K, Van Baelen A, Sprangers B, De Haes P

    Journal of medical case reports 2022; (16(1)):314 doi:10.1186/s13256-022-03477-6.

    PMID: 35989318
  4. 4

    Analysis of Anti-C1q Autoantibodies by Western Blot.

    Verlemyr A, Truedsson L, Skattum L

    Methods in molecular biology (Clifton, N.J.) 2019; (1901()):183-189 doi:10.1007/978-1-4939-8949-2_14.

    PMID: 30539577
  5. 5

    Childhood-onset hypocomplementaemic urticarial vasculitis in France: phenotypic and genotypic diversity in 10 children.

    Bianchi C, Melki I, Sisirak V, et al.

    Pediatric rheumatology online journal 2026; (24(1)).

    PMID: 41807955
  6. 6

    Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey.

    Krause K, Bonnekoh H, Jelden-Thurm J, et al.

    Clinical and translational allergy 2023; (13(10)):e12305 doi:10.1002/clt2.12305.

    PMID: 37876033
  7. 7

    Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis.

    Marzano AV, Maronese CA, Genovese G, et al.

    The Journal of allergy and clinical immunology 2022; (149(4)):1137-1149 doi:10.1016/j.jaci.2022.02.007.

    PMID: 35396080
  8. 8

    Diagnosis and management of leukocytoclastic vasculitis.

    Fraticelli P, Benfaremo D, Gabrielli A

    Internal and emergency medicine 2021; (16(4)):831-841 doi:10.1007/s11739-021-02688-x.

    PMID: 33713282
  9. 9

    A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria.

    Puhl V, Bonnekoh H, Scheffel J, et al.

    Clinical and translational allergy 2021; (11(2)):e12031 doi:10.1002/clt2.12031.

    PMID: 33949135
  10. 10

    Clinical Profile of Patients with Urticarial Vasculitis in China: A Retrospective of 142 Cases.

    Hu W, Zhu Y, Geng S, et al.

    Journal of inflammation research 2026; (19()):576374 doi:10.2147/JIR.S576374.

    PMID: 41877830
  11. 11

    Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis.

    Corthier A, Jachiet M, Bertin D, et al.

    BMC nephrology 2022; (23(1)):67 doi:10.1186/s12882-022-02689-8.

    PMID: 35172758
  12. 12

    Management of urticarial vasculitis: A worldwide physician perspective.

    Kolkhir P, Bonnekoh H, Kocatürk E, et al.

    The World Allergy Organization journal 2020; (13(3)):100107 doi:10.1016/j.waojou.2020.100107.

    PMID: 32180892

This page explains HUVS diagnostic criteria, laboratory tests, and biopsy terms for informational purposes only and does not constitute medical advice. Your treating clinician should interpret your results and guide follow-up.

Get notified when new evidence is published on Hypocomplementemic urticarial vasculitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.